Population pharmacokinetic/pharmacodynamic modelling of the hypothalamic-pituitary-gonadal axis

The present thesis deals with different aspects of population pharmacokinetic/ pharmacodynamic (PK/PD) modelling of the male hypothalamic-pituitary-gonadal (HPG) axis. The thesis consists of a summary report and five scientific research papers. An overview of the main topics covered in the thesis is provided in the summary report including PK/PD modelling in drug development, the pathological, physiological, and pharmacological aspects of the male HPG axis, and a detailed description of the methodology behind non-linear mixed-effects modelling based on stochastic differential equations (SDEs). The main objective of the work underlying this thesis was to develop mechanismbased population PK/PD models of the HPG axis. The HPG axis is a multivariate closed-loop control system consisting of regulatory hormonal feedback mechanisms. The number and complexity of the physiological mechanisms involved in such models makes them difficult to develop and are often too complex to be conveniently described by empirical models. Hence, the use of SDEs in population PK/PD modelling was used as a tool to systematically develop a mechanism-based model of the HPG axis following treatment with gonadotropin-releasing hormone (GnRH) agonist triptorelin and GnRH antagonist degarelix in a combined model. The use of SDEs in non-linear mixed-effects modelling was investigated by implementing the Extended Kalman Filter in the NONMEM software. Non-linear mixed-effects models based on SDEs extend the first-stage model of the hierarchical structure by decomposing the intra-individual variability into two types of noise, i.e. a system noise term representing unknown or incorrectly specified dynamics and a measurement noise term accounting for uncorrelated errors

[1]  A. Bartke,et al.  The Endocrine System , 1998, Alcohol health and research world.

[2]  William J Jusko,et al.  Diversity of mechanism-based pharmacodynamic models. , 2003, Drug metabolism and disposition: the biological fate of chemicals.

[3]  D. Bates,et al.  Approximations to the Log-Likelihood Function in the Nonlinear Mixed-Effects Model , 1995 .

[4]  Mats O. Karlsson,et al.  Automated Covariate Model Building Within NONMEM , 1998, Pharmaceutical Research.

[5]  L Aarons,et al.  Population pharmacokinetics: theory and practice. , 1991, British journal of clinical pharmacology.

[6]  Ewart R. Carson,et al.  The mathematical modeling of metabolic and endocrine systems : model formulation, identification, and validation , 1983 .

[7]  E. Nieschlag,et al.  LH-RH antagonists: state of the art and future perspectives. , 1992, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

[8]  E. Vonesh,et al.  A note on the use of Laplace's approximation for nonlinear mixed-effects models , 1996 .

[9]  W J Jusko,et al.  Physiologic indirect response models characterize diverse types of pharmacodynamic effects , 1994, Clinical pharmacology and therapeutics.

[10]  L. Goodman,et al.  The Pharmacological Basis of Therapeutics , 1941 .

[11]  Mats O. Karlsson,et al.  Three new residual error models for population PK/PD analyses , 1995, Journal of Pharmacokinetics and Biopharmaceutics.

[12]  M. O. Karlsson,et al.  The importance of modeling interoccasion variability in population pharmacokinetic analyses , 1993, Journal of Pharmacokinetics and Biopharmaceutics.

[13]  B. Dutrillaux,et al.  Clinical and experimental progression of a new model of human prostate cancer and therapeutic approach. , 2001, The American journal of pathology.

[14]  E Niclas Jonsson,et al.  More efficient clinical trials through use of scientific model‐based statistical tests , 2002, Clinical pharmacology and therapeutics.

[15]  W P Sheridan,et al.  Development of GnRH antagonists for prostate cancer: new approaches to treatment. , 2000, The oncologist.

[16]  M. Leider.  Goodman & Gilman's The Pharmacological Basis of Therapeutics , 1985 .

[17]  E. Niclas Jonsson.  Methodological studies on non-linear mixed effects model building , 1998 .

[18]  Robert Gurny,et al.  Biodegradable microparticles for sustained release of a new GnRH antagonist--part I: Screening commercial PLGA and formulation technologies. , 2003, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[19]  J M Kuhn,et al.  A randomized comparison of the clinical and hormonal effects of two GnRH agonists in patients with prostate cancer. , 1997, European urology.

[20]  G Martorana,et al.  Hormonal pattern and testicular histology in patients with prostatic cancer after long-term treatment with a gonadotropin-releasing hormone agonist analogue. , 1988, European urology.

[21]  D Jocham,et al.  [Effectiveness and tolerance of 1 dosage forms (subcutaneous and intramuscular) of decapeptyl depot in patients with advanced prostate carcinoma]. , 1999, Der Urologe. Ausg. A.

[22]  T. Başar,et al.  A New Approach to Linear Filtering and Prediction Problems , 2001 .

[23]  J. Huirne,et al.  Gonadotropin-releasing-hormone-receptor antagonists , 2001, The Lancet.

[24]  Jan Nygaard Nielsen,et al.  Parameter estimation in stochastic differential equations: An overview , 2000 .

[25]  C. R. Deboor,et al.  A practical guide to splines , 1978 .

[26]  I. Clarke,et al.  Negative Feedback Regulation of the Secretion and Actions of Gonadotropin-Releasing Hormone in Males , 2001, Biology of reproduction.

[27]  Lewis B. Sheiner,et al.  The Need for Mixed-Effects Modeling with Population Dichotomous Data , 2001, Journal of Pharmacokinetics and Pharmacodynamics.

[28]  H. Stricker,et al.  Luteinizing hormone-releasing hormone antagonists in prostate cancer. , 2001, Urology.

[29]  Ross Ihaka,et al.  Gentleman R: R: A language for data analysis and graphics , 1996 .

[30]  Hui C. Ko,et al.  Convergence of direct and indirect pharmacodynamic response models , 1995, Journal of Pharmacokinetics and Biopharmaceutics.

[31]  Sten Bay Jørgensen,et al.  A method for systematic improvement of stochastic grey-box models , 2004, Comput. Chem. Eng..

[32]  L B Sheiner,et al.  Simultaneous modeling of pharmacokinetics and pharmacodynamics: application to d-tubocurarine. , 1980, Clinical pharmacology and therapeutics.

[33]  A. Schally,et al.  Inhibition of growth of experimental prostate cancer with sustained delivery systems (microcapsules and microgranules) of the luteinizing hormone-releasing hormone antagonist SB-75. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[34]  Henrik Madsen,et al.  Grey-box pharmacokinetic/pharmacodynamic modelling of a euglycaemic clamp study , 2004, Journal of mathematical biology.

[35]  C G Brook,et al.  The relationship between endogenous testosterone and gonadotrophin secretion , 1993, Clinical Endocrinology.

[36]  L Aarons,et al.  Role of modelling and simulation in Phase I drug development. , 2001, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[37]  M Danhof,et al.  Analysis of drug-receptor interactions in vivo: a new approach in pharmacokinetic-pharmacodynamic modelling. , 1997, International journal of clinical pharmacology and therapeutics.

[38]  Carl de Boor,et al.  A Practical Guide to Splines , 1978, Applied Mathematical Sciences.

[39]  Robert Gurny,et al.  Biodegradable PLGA microparticles for sustained release of a new GnRH antagonist: part II. In vivo performance. , 2004, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[40]  R. E. Kalman,et al.  New Results in Linear Filtering and Prediction Theory , 1961 .

[41]  R. Williams,et al.  Williams Textbook of endocrinology , 1985 .

[42]  Henrik Madsen,et al.  Population Pharmacokinetic Modeling of a Subcutaneous Depot for GnRH Antagonist Degarelix , 2004, Pharmaceutical Research.

[43]  J. Rivier,et al.  GnRH antagonists: a new generation of long acting analogues incorporating p-ureido-phenylalanines at positions 5 and 6. , 2001, Journal of medicinal chemistry.

[44]  H. Madsen,et al.  Non-Linear Mixed-Effects Models with Stochastic Differential Equations: Implementation of an Estimation Algorithm , 2005, Journal of Pharmacokinetics and Pharmacodynamics.

[45]  E. Niclas Jonsson,et al.  Perl-speaks-NONMEM (PsN) - a Perl module for NONMEM related programming , 2004, Comput. Methods Programs Biomed..

[46]  Thomas Layloff,et al.  Analytical methods validation: Bioavailability, bioequivalence and pharmacokinetic studies , 1992 .

[47]  L Aarons.  Pharmacokinetic and pharmacodynamic modelling in drug development. , 1999, Statistical methods in medical research.

[48]  Henrik Madsen,et al.  Non-linear mixed-effects pharmacokinetic/pharmacodynamic modelling in NLME using differential equations , 2004, Comput. Methods Programs Biomed..

[49]  Mats O. Karlsson,et al.  Assessment of Actual Significance Levels for Covariate Effects in NONMEM , 2001, Journal of Pharmacokinetics and Pharmacodynamics.

[50]  Lewis B. Sheiner,et al.  Simultaneous vs. Sequential Analysis for Population PK/PD Data I: Best-Case Performance , 2003, Journal of Pharmacokinetics and Pharmacodynamics.

[51]  J Casselman,et al.  Long term experience in the treatment of advanced prostatic cancer with decapeptyl, compared to orchiectomy. , 1988, Acta urologica Belgica.

[52]  Sten Bay Jørgensen,et al.  Parameter estimation in stochastic grey-box models , 2004, Autom..

[53]  J. L. Roux.  An Introduction to the Kalman Filter , 2003 .

[54]  Russell D. Wolfinger,et al.  Laplace's approximation for nonlinear mixed models. , 1993 .

[55]  John Trachtenberg,et al.  A phase 3, multicenter, open label, randomized study of abarelix versus leuprolide plus daily antiandrogen in men with prostate cancer. , 2002, The Journal of urology.

[56]  Jean E Rivier,et al.  Pharmacological profile of a new, potent, and long-acting gonadotropin-releasing hormone antagonist: degarelix. , 2002, The Journal of pharmacology and experimental therapeutics.

[57]  R P Millar,et al.  Metabolic clearance and plasma half-disappearance time of D-TRP6 and exogenous luteinizing hormone-releasing hormone. , 1982, The Journal of clinical endocrinology and metabolism.

[58]  L. Petzold.  Automatic Selection of Methods for Solving Stiff and Nonstiff Systems of Ordinary Differential Equations , 1983 .

[59]  E N Jonsson,et al.  Xpose--an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM. , 1999, Computer methods and programs in biomedicine.

[60]  M. Kenward,et al.  An Introduction to the Bootstrap , 2007 .

[61]  Stuart L. Beal,et al.  Ways to Fit a PK Model with Some Data Below the Quantification Limit , 2001, Journal of Pharmacokinetics and Pharmacodynamics.

[62]  L Aarons,et al.  Population pharmacokinetics. , 1992, International journal of clinical pharmacology, therapy, and toxicology.

[63]  A. Schally,et al.  The LHRH antagonist cetrorelix: a review. , 2000, Human reproduction update.

[64]  Lewis B. Sheiner,et al.  A general conceptual model for non-steady state pharmacokinetic/Pharmacodynamic data , 2006, Journal of Pharmacokinetics and Biopharmaceutics.

[65]  Jon Wakefield,et al.  Population modelling in drug development , 1999, Statistical methods in medical research.

[66]  D. Klingmüller,et al.  Gonadotropin-releasing hormone: physiological and endocrinological aspects. , 1992, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

[67]  J. Isaacs,et al.  Sustained release formulations of luteinizing hormone-releasing hormone antagonist SB-75 inhibit proliferation and enhance apoptotic cell death of human prostate carcinoma (PC-82) in male nude mice. , 1992, Cancer research.

[68]  P. Welling,et al.  Pharmacokinetics: Processes and Mathematics , 1986 .

[69]  Andrzej Bartke,et al.  The Endocrine System , 1998, Alcohol health and research world.

[70]  M O Karlsson,et al.  Dose dependent absorption and linear disposition of cyclosporin A in rat , 1994, Biopharmaceutics & drug disposition.

[71]  L. Sheiner,et al.  Evaluating Pharmacokinetic/Pharmacodynamic Models Using the Posterior Predictive Check , 2001, Journal of Pharmacokinetics and Pharmacodynamics.

[72]  L. Skovgaard.  NONLINEAR MODELS FOR REPEATED MEASUREMENT DATA. , 1996 .

[73]  Stuart L. Beal,et al.  Interaction between structural, statistical, and covariate models in population pharmacokinetic analysis , 1994, Journal of Pharmacokinetics and Biopharmaceutics.

[74]  E. H. Twizell.  The mathematical modeling of metabolic and endocrine systems: E.R. Carson, C. Cobelli and L. Finkelstein John Wiley and Sons, Chichester, Sussex, UK, 394 pp., £45.15, 1983 , 1984 .

[75]  L B Sheiner,et al.  Pharmacokinetic/pharmacodynamic modeling in drug development. , 2000, Annual review of pharmacology and toxicology.

[76]  Henrik Madsen,et al.  Grey-box Modelling of Pharmacokinetic /Pharmacodynamic Systems , 2004, Journal of Pharmacokinetics and Pharmacodynamics.

[77]  Innovation OR Stagnation.  Challenge and Opportunity on the Critical Path to New Medical Products , 2004 .

[78]  V. Carey,et al.  Mixed-Effects Models in S and S-Plus , 2001 .

[79]  M Kovacs,et al.  Comparison of mechanisms of action of luteinizing hormone-releasing hormone (LHRH) antagonist cetrorelix and LHRH agonist triptorelin on the gene expression of pituitary LHRH receptors in rats , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[80]  Sten Bay Jørgensen,et al.  Fed-Batch Process Modelling for State Estimation and Optimal Control , 2002 .

[81]  T. Guthrie,et al.  Prostate cancer. , 2020, American family physician.

[82]  L B Sheiner,et al.  Modeling a bivariate control system: LH and testosterone response to the GnRH antagonist antide. , 1996, The American journal of physiology.